Loading…
Loading…
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com
Sheridan, Wyoming, USA, July 04, 2024 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA) - Rafarma Pharmaceuticals is pleased to announce its participation in the scientific conference on radioembolization using Yttrium 90 microspheres for the treatment of cancer at Severance Hospital in Seoul, South Korea. It is one of the largest university hospitals in South Korea and is of strategic importance to the country.
Sheridan, Wyoming, USA, July 03, 2024 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA) - Rafarma Pharmaceuticals is pleased to announce the signing of a preliminary agreement to establish a joint industrial venture in Busan Technology Park (South Korea) as the Dongnam Industrial Park of Radiological & Medical Sciences. The partners in the venture are Rafarma and the Korean pharmaceutical company Woods Medical Care.
Wyoming, USA, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA) - We are pleased to announce that Rapharma and its CEO Raivo Unt have entered into a preliminary agreement with Kelun Lifesciences (Pvt) Ltd, a pharmaceutical company based in Sri Lanka, on 17 November 2023. It is Sri Lanka's first and only pharmaceutical manufacturing facility for sterile liquid injections and infusions. The headquarters of the company is based in Kandy on the island of Sri Lanka.
Russia, Moscow, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA). The Company is pleased to announce that it has completed the restructuring, accounting and balance sheet procedures required to comply with GAAP auditing standards.
Nicosia, Cyprus, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) and one of the world's largest producers of precious metals, Krastsvetmet (Russia, Krasnoyarsk), discussed implementing a joint project to produce the most popular platinum-based chemotherapy drugs. If successful, the capacity of the production line for potent, highly active, platinum-based pharmaceuticals will be up to one ton per year with the possibility of increasing and expanding the list of drugs.
Nicosia, Cyprus, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC: (RAFA) shares the following letter to shareholders from Chairman of the Board Ilya Shpurov:
Nicosia, Cyprus, July 30, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) The scientific and technical council of the Agency for the Development of the Pharmaceutical Industry of Uzbekistan recognized the Rafarma Pharmaceuticals' project for the construction of the Tashkent plant as the largest innovative project of the industrial zone of the Tashkent Pharma Park pharmaceutical cluster.
No recent filings indexed.